GT200500139A - Metodo para la preparacion de acidos hidroxamicos - Google Patents

Metodo para la preparacion de acidos hidroxamicos

Info

Publication number
GT200500139A
GT200500139A GT200500139A GT200500139A GT200500139A GT 200500139 A GT200500139 A GT 200500139A GT 200500139 A GT200500139 A GT 200500139A GT 200500139 A GT200500139 A GT 200500139A GT 200500139 A GT200500139 A GT 200500139A
Authority
GT
Guatemala
Prior art keywords
preparation
hydroxamic acids
hydroxamic
acids
intermediaries
Prior art date
Application number
GT200500139A
Other languages
English (en)
Inventor
Ting-Zhong Wang
Lalitha Krishnan
Joseph Zeldis
Jeremy I Levin
Jean Schmid
Melllard N Jennings
Huan-Qiu Li
Zhixin Wen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200500139A publication Critical patent/GT200500139A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

LA PRESENTE INVENCION SE RELACINOA CON PROCESOS PARA LA PREPARACION DE ACIDOS HIDROXAMICOS Y CON DERIVADOS E INTERMEDIARIOS DE LOS MISMOS.
GT200500139A 2004-06-08 2005-06-06 Metodo para la preparacion de acidos hidroxamicos GT200500139A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57778404P 2004-06-08 2004-06-08

Publications (1)

Publication Number Publication Date
GT200500139A true GT200500139A (es) 2005-07-25

Family

ID=35106941

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200500139A GT200500139A (es) 2004-06-08 2005-06-06 Metodo para la preparacion de acidos hidroxamicos

Country Status (6)

Country Link
US (2) US7435732B2 (es)
AR (2) AR049349A1 (es)
GT (1) GT200500139A (es)
PA (2) PA8636101A1 (es)
TW (2) TW200610523A (es)
WO (2) WO2005123705A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
GT200500139A (es) * 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos
PL2444079T3 (pl) 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
FR2898497B1 (fr) * 2006-03-20 2008-05-16 Galderma Res & Dev Utilisation de l'apratastat ou du (s)-n-hydroxy-4-(4-but-2- ynyloxy-benzenesulfonyl)-2,2-dimethyl-thiomorpholine-3-carbo xamide dans le traitement de pathologies inflammatoires cutanees
US7631568B2 (en) * 2007-08-28 2009-12-15 Quest Technologies Particulate monitor
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
EP2496079A4 (en) 2009-11-06 2014-05-14 Pierre Fabre Médicament Sas NOVEL (1S, 2R) -2- (AMINOMETHYL) -N, N-DIETHYL-1-PHENYLCYCLOPROPANECARBOXAMIDE CRYSTALLINE FORMS
EP3715345B1 (en) 2012-07-25 2024-04-10 Novartis AG Preparation of lfa-1 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020824A1 (en) * 1995-12-08 1997-06-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
NZ336836A (en) * 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
US6225311B1 (en) * 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6387901B1 (en) * 1999-07-06 2002-05-14 Pfizer Inc Alkyne containing metalloproteinase inhibitors
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
BR0213736A (pt) 2001-11-01 2004-10-19 Wyeth Corp ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
GT200500139A (es) * 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos

Also Published As

Publication number Publication date
PA8636301A1 (es) 2006-03-24
PA8636101A1 (es) 2006-03-24
TW200612959A (en) 2006-05-01
AR049073A1 (es) 2006-06-21
US7179911B2 (en) 2007-02-20
US7435732B2 (en) 2008-10-14
AR049349A1 (es) 2006-07-19
WO2005123705A1 (en) 2005-12-29
US20050272928A1 (en) 2005-12-08
WO2005123706A9 (en) 2006-04-27
US20050272929A1 (en) 2005-12-08
WO2005123706A1 (en) 2005-12-29
TW200610523A (en) 2006-04-01

Similar Documents

Publication Publication Date Title
GT200500139A (es) Metodo para la preparacion de acidos hidroxamicos
ECSP077321A (es) Procesos e intermediarios para preparar inhibidores de cisteína proteasa
ECSP066467A (es) Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona
CR8519A (es) Nuevos pirrolocarbazoles fusionados
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
PA8618901A1 (es) Biaril sulfonamidas y metodo para el uso de las mismas
PA8693101A1 (es) Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso
AR057253A1 (es) Anticuerpos anti-ox40l y metodos que los utilizan
CR20180142A (es) ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
BRPI0516735B8 (pt) métodos para produção de (r)-2-acetamido-n-benzil-3-metoxipropionamida (lacosamida) e de uma formulação farmacêutica, e uso de (r)-n-benzil-2-nboc-amino-3-metoxipropionamida (c-937)
SV2008002542A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar los mismos ref. 01142.0379-00267 (am101946sv)
CR11139A (es) Anticuerpos anti-notch1 nrr y sus metodos de uso
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
HN2006035237A (es) Derivados de triazolopiridina en calidad de inhibidores de lipasas y fosfolipasas
BRPI0615029A2 (pt) processos e intermediários
ECSP078032A (es) Modificaciones cristalinas de la piraclostrobina
PA8526501A1 (es) Proceso para la fabricacion de acidos n-aril-antranilicos y sus derivados
BRPI0514584A (pt) método para preparar irbesartan e intermediários do mesmo
EA200702464A1 (ru) Способы получения фенольных 4-бифенилилазетидин-2-онов
HN2006029142A (es) Proceso
CY1109992T1 (el) Παραγωγα του αλφα-αμιναμιδιου χρησιμα ως αντιφλεγμονωδη μεσα
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
ECSP088383A (es) Tetrahidroquinolinas, su síntesis e intermediarios campo de la invención
AR059096A1 (es) Anticuerpos anti- efrina -b2 y metodos que usan estos
PA8653801A1 (es) Derivados de octahidropirrolo [3,4-c] pirrol